ZA200204019B - Combination treatment for alcoholism and alcohol dependence. - Google Patents

Combination treatment for alcoholism and alcohol dependence.

Info

Publication number
ZA200204019B
ZA200204019B ZA200204019A ZA200204019A ZA200204019B ZA 200204019 B ZA200204019 B ZA 200204019B ZA 200204019 A ZA200204019 A ZA 200204019A ZA 200204019 A ZA200204019 A ZA 200204019A ZA 200204019 B ZA200204019 B ZA 200204019B
Authority
ZA
South Africa
Prior art keywords
alcoholism
combination treatment
alcohol dependence
dependence
alcohol
Prior art date
Application number
ZA200204019A
Other languages
English (en)
Inventor
Howard Harry Ralph Jr
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Publication of ZA200204019B publication Critical patent/ZA200204019B/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Addiction (AREA)
  • Psychiatry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
ZA200204019A 2001-05-23 2002-05-21 Combination treatment for alcoholism and alcohol dependence. ZA200204019B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US29308801P 2001-05-23 2001-05-23

Publications (1)

Publication Number Publication Date
ZA200204019B true ZA200204019B (en) 2003-11-21

Family

ID=23127615

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA200204019A ZA200204019B (en) 2001-05-23 2002-05-21 Combination treatment for alcoholism and alcohol dependence.

Country Status (11)

Country Link
US (2) US20030130322A1 (OSRAM)
EP (1) EP1262196A3 (OSRAM)
JP (1) JP2002370975A (OSRAM)
KR (1) KR20020090153A (OSRAM)
CN (1) CN1386503A (OSRAM)
AU (1) AU4068602A (OSRAM)
CA (1) CA2386740A1 (OSRAM)
HU (1) HUP0201722A2 (OSRAM)
NZ (1) NZ519032A (OSRAM)
PL (1) PL354110A1 (OSRAM)
ZA (1) ZA200204019B (OSRAM)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL1617832T3 (pl) * 2003-04-29 2009-01-30 Orexigen Therapeutics Inc Kompozycje wpływające na utratę wagi
US8758443B2 (en) 2005-05-06 2014-06-24 Titan Spine, Llc Implants with integration surfaces having regular repeating surface patterns
EP1951212A2 (en) 2005-11-22 2008-08-06 Orexigen Therapeutics, Inc. Compositions and methods for increasing insulin sensitivity
WO2007089318A2 (en) * 2005-11-23 2007-08-09 Orexigen Therapeutics, Inc. Compositions and methods for reducing food cravings
EP1954316A1 (en) * 2005-11-28 2008-08-13 Orexigen Therapeutics, Inc. Methods of treating anxiety disorders
US8916195B2 (en) 2006-06-05 2014-12-23 Orexigen Therapeutics, Inc. Sustained release formulation of naltrexone
KR20090090316A (ko) 2006-11-09 2009-08-25 오렉시젠 세러퓨틱스 인크. 체중 감량 약물을 투여하기 위한 단위 용량 팩키지 및 투여 방법
KR20190042766A (ko) 2006-11-09 2019-04-24 오렉시젠 세러퓨틱스 인크. 신속하게 용해되는 중간층을 포함하는 층상의 약제학적 제형
MX2009006672A (es) * 2006-12-19 2009-10-26 Univ Virginia Efectos combinados de topiramato y ondansetron sobre el consumo de alcohol.
HRP20130621T1 (en) 2008-02-28 2013-09-30 University Of Virginia Patent Foundation Serotonin transporter gene and treatment of alcoholism
JP2011521973A (ja) 2008-05-30 2011-07-28 オレキシジェン・セラピューティクス・インコーポレーテッド 内臓脂肪の状態を処置するための方法
CN102724878A (zh) 2010-01-11 2012-10-10 奥雷西根治疗公司 在重度抑郁症患者中提供体重减轻疗法的方法
NZ605709A (en) 2010-07-02 2014-08-29 Univ Virginia Patent Found Molecular genetic approach to treatment and diagnosis of alcohol and drug dependence
US20130096173A1 (en) 2011-09-09 2013-04-18 Bankole A. Johnson Molecular genetic approach to treatment and diagnosis of alcohol and drug dependence
PL3730132T3 (pl) 2012-06-06 2022-10-10 Nalpropion Pharmaceuticals Llc Kompozycja do zastosowania w sposobie leczenia nadwagi i otyłości u pacjentów z wysokim ryzykiem sercowo-naczyniowym
CN114588467B (zh) * 2022-04-01 2022-11-29 广州蓝仕威克医疗科技有限公司 一种基于气体混合比例供气解决酒精中毒的方法及呼吸机
CN115671107B (zh) * 2022-12-29 2023-04-04 文韬创新药物研究（北京）有限责任公司 用于解酒的复方药物组合物

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA923283B (en) * 1991-05-29 1993-01-27 Akzo Nv Phenoxyphenyl derivatives
DE69525847T2 (de) * 1994-09-19 2002-09-05 Dupont Pharmaceuticals Co., Wilmington Zusammensetzungen von opioid antagonisten mit selektiven serotonin-aufnahme inhibitoren, zur behandlung von alkoholismus und alkohoabhängigkeit
US5948807A (en) * 1997-09-03 1999-09-07 Regents Of The University Of Minnesota Spiroindanamines and Spiroindanimides
EP0945133A1 (en) * 1998-03-26 1999-09-29 Lipha Combination for the treatment of alcohol and drug dependence containing an opioid antagonist and a NMDA receptor complex modulator
WO2000050380A1 (en) * 1999-02-23 2000-08-31 Pfizer Products Inc. Monoamine reuptake inhibitors for treatment of cns disorders
US6071918A (en) * 1999-07-21 2000-06-06 Dupont Pharmaceuticals Company Combination of an opioid antagonist and a selective serotonin reuptake inhibitor for treatment of alcoholism and alcohol dependence
AU769430B2 (en) * 1999-10-13 2004-01-29 Pfizer Products Inc. Biaryl ether derivatives useful as monoamine reuptake inhibitors

Also Published As

Publication number Publication date
NZ519032A (en) 2003-10-31
AU4068602A (en) 2002-12-05
HU0201722D0 (OSRAM) 2002-07-29
EP1262196A2 (en) 2002-12-04
PL354110A1 (en) 2002-12-02
HUP0201722A2 (hu) 2003-07-28
JP2002370975A (ja) 2002-12-24
US20040162316A1 (en) 2004-08-19
EP1262196A3 (en) 2002-12-18
KR20020090153A (ko) 2002-11-30
US20030130322A1 (en) 2003-07-10
CN1386503A (zh) 2002-12-25
CA2386740A1 (en) 2002-11-23

Similar Documents

Publication Publication Date Title
ZA200204020B (en) Use of anti-CTLA-4-antibodies.
MXPA03009647A (es) Heterociclildicarbamidas como inhibidores de caspasa.
AU2001260513A1 (en) Microcapsule well treatment
ZA200208561B (en) Hydraulischer druckverstarker.
MXPA01009037A (es) I-bet.
ZA200204019B (en) Combination treatment for alcoholism and alcohol dependence.
ZA200201866B (en) Valve device.
GB0113493D0 (en) Parking aid
GB2392483B (en) Work-assembling auxiliary device, and work-assembling process
MXPA03005286A (es) METODO Y APARATO PARA SUPERVISAR PULSACION DE INSTALACION DE ORDEnA.
MXPA03008139A (es) Fluoralcoxifenilsulfonilureas sustituidas.
GB2380037B (en) Recognition system
GB0127384D0 (en) Well treatment system
MXPA03007596A (es) Lacas de poliuretano de 1c de secado al horno y su uso.
ZA200204018B (en) Combination treatment for depression and anxiety.
GB2376239B (en) Cask treatment
GB2389165B (en) Valve system
ZA200204985B (en) Activated rec-D-hydantoinases.
IL149703A0 (en) Combination treatment for alcoholism and alcohol dependence
GB0105446D0 (en) S.s.h.p.s
HU0104096D0 (en) Bottled wine-and-soda
GB0116210D0 (en) P.c.o
GB0118494D0 (en) P.c.o.
ZA200206978B (en) Gravestone.
CA93107S (en) Vehicle footrest